Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 163.83 |
---|---|
High | 169.71 |
Low | 160.18 |
Bid | 168.04 |
Offer | 178.55 |
Previous close | 162.10 |
Average volume | 2.18m |
---|---|
Shares outstanding | 123.68m |
Free float | 118.80m |
P/E (TTM) | -- |
Market cap | 20.76bn USD |
EPS (TTM) | -1.77 USD |
Data delayed at least 15 minutes, as of Nov 20 2024 21:00 GMT.
More ▼
- Natera Reports Third Quarter 2024 Financial Results
- Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
- Natera to Participate in Upcoming Investor Conferences
- Natera to Report its Third Quarter 2024 Results on November 12, 2024
- Natera to Present New Renasight Data at ASN Kidney Week 2024
- Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
- Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
- First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
- Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
- Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
More ▼